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SUMMARY
SETTING—Rural community in South India.
OBJECTIVE—To determine the role of bacille Calmette-Guérin (BCG) in preventing tuberculous 
infection in children.
DESIGN—A prevalence survey was undertaken in 1999–2001 in a representative rural population 
in Tiruvallur District in South India using cluster sampling. Tuberculin testing was performed 
among all children aged <15 years, and all adults aged ⩾15 years were questioned about chest 
symptoms and underwent radiography, followed by sputum examinations, if indicated.
RESULTS—In children living in households with a tuberculosis case, the proportion with 
evidence of tuberculous infection was 35.5% of 200 in the absence of a BCG scar and 27.0% of 
100 in its presence, a reduction of 24% (P = 0.14). In very young children (age <5 years), the 
corresponding proportions were 29.1% of 55 and 11.9% of 42, a reduction of 59%; the difference 
was statistically significant (P = 0.048).
CONCLUSION—There is a possible role for BCG in preventing tuberculous infection in very 
young children.
Keywords
survey; tuberculous infection; BCG; epidemiology; community
Several Randomised Trials have been undertaken to determine the protective efficacy of 
bacille Calmette-Guérin (BCG) vaccination against tuberculosis (TB) disease. Results have 
shown that the protective efficacy of BCG ranges between 0% and 80%;1–3 efficacy is lower 
in tropical and subtropical latitudes with a high disease burden4 and due to exposure to non-
tuberculous mycobacteria (NTM) or sunlight, or where there is a poor cold chain.5 In the 
1950s, a Medical Research Council study in the United Kingdom, reported an 80% efficacy 
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of BCG;1 however, a study in South India conducted in the 1970s showed no protective 
efficacy.2,3 Among children, the protective efficacy of BCG against meningeal and miliary 
TB was 86% in randomised control trials and 75% in case-control studies.6 A 2006 meta-
analysis yielded similar findings: 73% for tuberculous meningitis and 77% for miliary TB.7
There has been some discussion about whether BCG-vaccinated subjects have a lower risk 
of disease because the vaccine prevents tuberculous infection in uninfected persons, or 
whether it only lessens the risk of progression to disease in those infected. A 2014 meta-
analysis in children, based on electronic database searches from 1950 to 2013, concluded 
that BCG offers both types of protection.8 This publication inspired us to retrospectively 
examine the data from one of our rural prevalence surveys9 to investigate the hypothesis that 
BCG prevents tuberculous infection in children. The study findings are reported here.
METHODOLOGY
A prevalence survey was undertaken in 1999–2001 in a random sample of 50 of 208 villages 
and 3 of 10 urban units in five panchayat unions (blocks), Ellapuram, Kadambathur, Poondi, 
Tiruvallur and Tiruvalangadu, in the BCG trial area of Tiruvallur District, Tamil Nadu, 
India.9 A cluster sampling design was adopted. All permanent residents aged ⩾15 years in 
the selected clusters were questioned about chest symptoms and underwent chest 
radiography (CXR). Two sputum specimens, collected from those with abnormal CXR 
and/or chest symptoms, were examined using fluorescence microscopy and cultured on 
Löwenstein-Jensen medium; all positive culture specimens were subjected to identification 
tests. All children underwent the tuberculin skin test (TST) using 1 tuberculin unit (TU) (RT 
23 with Tween 80). Full details have been published elsewhere.9
Definition of a TB case
A TB case was defined as a person with a positive culture, irrespective of sputum smear 
microscopy result.
Strain of BCG
All study subjects with a BCG scar received the Danish BCG strain 1331.
Definition of tuberculous infection
In 12 854 children aged <10 years, the distribution of TST results with 1 TU RT 23 (with 
Tween 80) suggested an anti-mode of 12 mm. Using the ‘discrimination’ method described 
by Canetti et al.,10 a cut-off of 12 mm was chosen as it best discriminated between these 
children, relatively few of whom were likely to have been infected, and 472 confirmed cases 
of culture-positive TB. An induration of ⩾12 mm was therefore taken as indicative of 
tuberculous infection.
Ranking of predictors
Unlike in the case of multiple linear regression, there is no universal agreement on how best 
to rank predictors, and several methods have been described in the literature.11 Of these, 
‘adequacy’, defined as the proportion of the full model log-likelihood that is explainable by 
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each predictor individually,12 was chosen for ranking purposes in this paper, because it is 
analogous to the individual characteristic’s contribution to the total R2 (where R is the 
multiple correlation coefficient) in multiple linear regression. Three other methods were also 
investigated: logistic pseudo partial correlation, P value of the Wald χ2 test and concordance 
statistics.
RESULTS
Influence of bacille Calmette-Guérin vaccination on tuberculin skin test sensitivity
Table 1 shows the association between the prevalence of TST positivity and various 
characteristics. Univariate analyses showed that the likelihood of a positive TST result 
increased substantially with age and the presence of a TB case in the household (P < 
0.0001). Sex was not correlated (P = 0.8), but the presence of a BCG scar was associated 
with a lower prevalence of infection (12.2 vs. 14.7%, P < 0.0001). As these characteristics 
are interrelated, multivariate logistic regression was performed, which confirmed the 
importance of age and type of household (Table 2). However, the interaction between 1) age 
and type of household, and 2) age and BCG scar were both statistically significant. These 
findings suggested that separate analyses by BCG scar and age in households with/without a 
TB case would be more informative. The proportions of TST-positive patients in the various 
subgroups are given in Table 3.
In households with at least one TB case, the overall proportion of TST-positive patients was 
35.5% in those without a BCG scar and 27.0% in those with a scar (Table 3), representing a 
reduction of 24% (95% confidence interval [CI] 0–48) in those who had received BCG (P = 
0.14). However, a formal analysis of variance (not given here) showed that there was some 
evidence of an interaction between age and BCG. This led us to examine the effect of BCG 
in each of the three age groups. In children aged <5 years, the difference was significant 
(29.1% of 55 vs. 11.9% of 42, P = 0.048). In children aged 5–9 years, the corresponding 
proportions were 27.4% of 62 and 32.4% of 34 (P = 0.6), and in those aged 10–14 years the 
proportions were identical (both 45.8%) (Table 3).
In households with no TB case, the interaction between age and BCG was non-significant; 
the overall proportion of TST positivity in children aged 0–14 years was 14.3% of 9513 in 
children with no BCG scar compared to 12.0% of 6571 in children with a scar, a significant 
reduction (P < 0.001). However, those with a scar were substantially younger (38% vs. 24% 
aged <5 years, P < 0.0001); when this difference was taken into account, the direction of the 
difference was reversed, with the standardised percentages being lower—12.9% in those 
with no BCG scar and 14.3% in those with a scar. In all children aged <5 years, presence of 
BCG scar was associated with type of household (P = 0.048), which further confirmed that, 
as in this study, study findings in houses with/without a TB case should be examined 
separately. Our findings suggest that BCG has a protective effect against tuberculous 
infection in children aged <5 years, but only in households with recent exposure to TB.
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Ranking of predictors
The ranking of various prognostic characteristics, as determined by the adequacy criterion, 
was as follows: age, type of household (with/without TB case), BCG scar (absence/
presence) and sex; the corresponding contributions to total likelihood were respectively 
8.82%, 0.60%, 0.17% and 0.0004%. The remaining three ranking methods investigated— 
logistic pseudo partial correlation, P value using Wald’s χ2 test and concordance statistic—
confirmed first and second rank for age and type of household, but showed that the third and 
fourth ranks were interchangeable between BCG scar status and sex. Agreement between the 
four ranking methods was thus almost perfect (coefficient of concordance 0.90).
Analysis in other subsets
All analyses were performed in a representative sample of 16 384 children aged <15 years 
from 53 clusters. They were also performed in an additional 4805 children from the 
remaining 14 clusters in Tiruvelangadu and Kadambathur; thus findings from a total of 21 
189 children from 67 clusters were examined. These confirmed the conclusions reported 
above, and in particular, the difference between children with and without a BCG scar in 
households with at least one TB case, 34.8% of 230 vs. 28.5% of 123, a reduction of 18% 
(95%CI 0–41) in children who had received BCG (P = 0.23).
DISCUSSION
Retrospective analysis of the data from the rural prevalence survey9 showed that in 
households with a TB case, 29.1% of 55 children aged <5 years without a BCG scar were 
TST-positive compared to 11.9% of 42 children with a BCG scar, a reduction of 59%. In all 
children aged <15 years, the corresponding proportions were 35.5% and 27.0%, and the 
difference was 24% (95%CI 0–48). As the two groups were not obtained using random 
sampling, it could be argued that the lower prevalence of infection in those with a BCG scar 
may be because parents who chose to have their children BCG-vaccinated were 
economically better off and more knowledgeable about health risks to children. Another 
limitation in attributing the reduction in infection to BCG vaccination per se was that our 
definition of infection was based on the outcome of the standard TST, which does not 
distinguish between infection by Mycobacterium tuberculosis and that caused by BCG 
vaccination or infection due to NTM. In a country with a policy of BCG vaccination at birth 
and a notable prevalence of NTM infection,13 their impact may have had a confounding 
effect.
A recently developed technique, the T-cell-based interferon-gamma release assay (IGRA), 
has the capacity to detect tuberculous infection and, more importantly, distinguish it from 
previous BCG vaccination and most NTM infections. Based on the outcome of IGRAs, a 
meta-analysis of 14 studies including 3855 participants demonstrated a protective effect of 
19% (95%CI 8–29) against tuberculous infection in participants aged ≤15 years who had 
had recent exposure to TB patients;13 in a subset of five studies involving 1862 children who 
were simultaneously exposed to a single well-defined source, BCG efficacy was slightly 
higher, at 28% (95%CI 0–48). The corresponding estimate from our study was similar, at 
24%.
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Our finding that the BCG vaccine protects against tuberculous infection in children is 
consistent with a previous publication from Turkey that yielded an odds ratio of 0.60 
(95%CI 0.43–0.83) for tuberculous infection compared with non-vaccinated children.14
Cost and complexity may make it difficult to use IGRAs in public health interventions. An 
attractive alternative could be the C-Tb skin test, developed by the Statens Serum Institute, 
Copenhagen, Denmark, which has been reported to be more specific than the TST.15
CONCLUSION
We believe that more studies on this subject are necessary with IGRAs and C-Tb skin tests 
in addition to, rather than instead of, the TST, in keeping with World Health Organization 
guidelines for latent tuberculous infection.16 Future trials of TB vaccines, especially in 
children, should include a component of protection against tuberculous infection in the 
outcome assessment, in addition to reduction in disease incidence.
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Table 1
Univariate correlates of tuberculin skin test positivity in children
Characteristic Subjects n Infected n (%) P value
Age, years <0.0001*
 0–4 4 897 172 (3.5)  
 5–9 5 686 674(11.9)
 10–14 5 801 1 399 (24.1)
Sex 0.83      
 Female 8 034 1 096 (13.6)
 Male 8 350 1 149 (13.8)
BCG scar <0.0001  
 Absent 9 713 1 428 (14.7)
 Present 6 671 817 (12.2)
Type of household <0.0001  
 No TB case 16 084 2 147 (13.3)
 ⩾1 TB case 300 98 (32.7)
 Total 16 384 2 245 (13.7)
*
Based on trend χ2 with 1 degree of freedom. BCG = bacille Calmette-Guérin; TB = tuberculosis.
Int J Tuberc Lung Dis. Author manuscript; available in PMC 2017 May 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Adinarayanan et al. Page 8
Table 2
Univariate and multivariate ORs for age, sex, BCG scar and presence of a TB case in the household
Characteristic Subjects n Univariate OR aOR (95%CI) P value
Age, years
 0–4 4 897 1.00 1.00
 5–9 5 686 3.69 3.89 (3.20–4.73) <0.0001
 10–14 5 801 8.73 9.1 (7.62–10.87) <0.0001
Sex
 Male 8 350 1.01 1.04 (0.95–1.14)   0.42
 Female 8 034 1.00 1.00
BCG scar
 Absent 9 713 1.00 1.00
 Present 6 671 0.81 0.91 (0.66–1.24)   0.55
Type of household
 No TB case 16 084 1.00 1.00
 ⩾1 TB case 300 3.15 8.51 (5.11–14.16) <0.0001
Interaction age × BCG scar
 BCG scar
  0–4 years 1.00
  5–9 years 1.08   0.32
  10–14 years 1.19   0.01
Interaction age × type of household
 ⩾1 TB case
  0–4 years 1.00
  5–9 years 0.37   0.004
  10–14 years 0.32   0.001
Interaction BCG scar × type of household
 ⩾ 1 TB case
  No scar 1.00
  Scar 0.75   0.30
Goodness-of-fit (Hosmer-Lemeshow χ2) 0.01 4 df   1.00
Overall correct predictions 86%
OR = odds ratio; BCG = bacille Calmette-Guérin; TB = tuberculosis; aOR = adjusted OR; CI = confidence interval; df = degrees of freedom.
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